These data imply that ANGPTL3 may be not only a therapeutic target in the treatment of RCC patients with sorafenib resistance but also a novel biomarker for predicting responsiveness to sorafenib treatment. The gene discussed is ANGPTL3; the disease is renal cell carcinoma.